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Abstract
Introduction Adalimumab, a humanized monoclonal anti-
body targeted against TNF-α, has proved to be successful
in the treatment of uveitis. Another anti-TNF-α agent, i.e.,
infliximab, has been reported of benefit in the treatment of
refractory sarcoidosis. The aim of this prospective case
series was to evaluate the effect of adalimumab on
intraocular inflammatory signs and other relevant clinical
manifestations (lung function, serological inflammatory
parameters, and fatigue) of sarcoidosis.
Methods Sarcoidosis patients with refractory posterior
uveitis (n=26, 17 females, 41 eyes in total) were system-
atically followed for 12 months after initiation of adalimu-
mab 40 mg sc once a week. Inclusion criteria were non-
responsiveness to prednisone and methotrexate (MTX) or
intolerance to these drugs. Adjunctive therapy with predni-
sone and MTX was tapered during treatment with adali-
mumab. Localization and improvement, stabilization or
deterioration of intraocular inflammatory signs was scored.
Pulmonary function- and laboratory testing were performed
and Fatigue Assessment Scale was completed. Results at
baseline, 6 months, and 12 months were compared.
Results Choroidal involvement resolved in 10/15 patients,
five had partial improvement; vasculitis resolved in 1/1
patient; papillitis resolved in 7/8 patients, one had partial
response; macular edema resolved in 5/8 patients, three had
partial response; vitreous cleared completely in 5/5 patients.
Overall outcome regarding intraocular inflammatory signs
showed improvement in 22 patients (85%) and stabilization
in four patients (15%). At 12 months, no recurrences were
reported in those successfully treated. Laboratory parame-
ters of inflammatory activity (C-reactive protein; serum
angiotensin-converting enzyme and soluble interleukin-2
Receptor) improved (p<0.01). Moreover, fatigue improved
in 14/21 (67%) of the patients suffering from fatigue and
the diffusion capacity for carbon monoxide (DLCO)
improved in 7/8 (88%) of patients with a decreased DLCO
(p<0.01). The dosage of both prednisone and MTX could
be tapered down significantly (p<0.01 and p<0.05,
respectively).
Conclusions Adalimumab appeared successful in sarcoido-
sis patients with refractory chronic non-infectious uveitis
showing improvement in intraocular inflammatory signs as
well as in other relevant clinical indicators of disease
activity. Future randomized studies are needed to determine
the optimal dosage, dose interval and duration of therapy in
refractory multisystemic sarcoidosis.
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Introduction
Uveitis is a sight-threatening eye disease inflicted by auto-
immune disorders or infectious agents [1]. Sarcoidosis is a
multisystemic granulomatous chronic disorder with un-
known etiology [2, 3]. In the eye this can cause uveitis with
anterior chamber cells and flare, corneal deposits, synechiae
formation, macular edema, vasculitis, retinitis, papillitis
and/or a vitritis [4]. Ocular manifestations of systemic
sarcoidosis have significant impact on visual prognosis [5,
6]. Sarcoidosis patients with chronic disease often require
prolonged treatment. Moreover, since sarcoidosis is a
systemic disease, the effect of treatment on the various
affected organs is important in deciding which therapy is
the most appropriate. Regarding eye involvement, interme-
diate uveitis, posterior uveitis and panuveitis all require
aggressive treatment regimen with immunosuppressive
drugs in order to preserve vision and function of the eye
[6, 7]. Corticosteroids remain the mainstay of treatment.
However, in case this treatment does not have a favorable
outcome or if disabling side-effects, which accompany
prolonged treatment occur, use of other alternative, steroid-
sparing agents is mandatory. Methotrexate has been proven
to be a good alternative [8]. In case this therapy also fails,
use of biologic agents which block tumor necrosis factor-
alpha (TNF-α) can provide effective treatment for the
diverse manifestations of sarcoidosis [9–11]. Among the
TNF-α inhibitors, infliximab has been studied most
extensively in sarcoidosis [9, 11–13]. Anti-TNF-α treat-
ment has been efficacious for the treatment of refractory
ocular inflammatory disease [7, 14–18].
Adalimumab, a humanized monoclonal antibody tar-
geted against TNF-α, has also been reported useful in
treating uveitis, sarcoidosis and various other auto-immune
disorders [9, 18–26]. The aim of this prospective case series
was to evaluate the effect of adalimumab on intraocular
inflammatory signs and other relevant clinical manifesta-
tions (lung function, laboratory inflammatory parameters,
and fatigue) in sarcoidosis patients with refractory chronic
non-infectious uveitis.
Materials and methods
All sarcoidosis patients referred to the sarcoidosis manage-
ment team of the Maastricht University Medical Centre
(MUMC), the Netherlands (a tertiary referral center), who
started treatment with the anti-TNF-α drug adalimumab
initiated by our ophthalmologist (RE) because of refractory
posterior uveitis between March 2006 and December 2009
were followed systematically according to a clinical
protocol for 12 months. Adalimumab was started based
on the following clinical criteria: patients with refractory
posterior uveitis who did not respond to the original therapy
with immunosuppressive drugs (both prednisone and
methotrexate; n=20) and patients who responded to
previous therapy with these immunosuppressive drugs, but
demonstrated severe adverse effects (n=6). It has to be
emphasized that in order to prescribe the drug in the
Netherlands for the treatment of uveitis, the patient had to
be treated with at least two different immunosuppressive
drugs, previously. Therefore, it is not allowed to use this
drug as first choice in treating severe uveitis. Adalimumab
was administrated at a dose of 40 mg subcutaneously once
a week. Patients were instructed to inject themselves and to
report side effects immediately. Only patients who were
treated with adalimumab for at least six months and
completed the follow-up period of 12 months were included
in the analysis (n=26).
The diagnosis sarcoidosis was based on consistent
clinical features and bronchoalveolar lavage fluid analysis,
in accordance with the WASOG guidelines with biopsy-
proven noncaseating epithelioid cell granulomas confirming
sarcoidosis in 21/26 (77%) patients [27]. None of these
patients had a relevant medical history or co-morbidity. At
initial diagnosis, the presence of active tuberculosis was
excluded. Just before initiating anti-TNF-alpha treatment a
Quantiferon®- TB Gold in combination with the tuberculin
skin test was repeated to exclude latent tuberculosis
infection (LTBI) as this is a contraindication for treatment
with TNF-α inhibitor therapy and also recommended in the
guidelines of our hospital [4, 28]. At both time points, these
tests were negative in all included patients.
Evaluation of clinical course
The different outcome measures were scored at baseline,
6 months and 12 months.
Evaluation of uveitis
All the patients were evaluated by the same ophthalmolo-
gist (RE). He screened the patients for the presence of
uveitis on the following items. Using slit-lamp examination
the eye was scrutinized on the presence of noduli in the
conjunctival tissue; corneal deposits; anterior chamber cells
and flare; anterior and posterior synechiae formation. These
findings are not included because in our cases the anterior
segment had no active signs of inflammation. In fact, 21
patients had no signs at all of uveitis anterior, while five
patients had uveitis anterior in the past that showed no
activity at the initial examination. Using funduscopy, the
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presence of macular edema, snowballs or vitreous opacities;
multiple chorioretinal peripheral lesions; nodular and/or
segmental periphlebitis and/or macroaneurysms or optic
disc nodules were recorded. The Standardization of Uveitis
Nomenclature (SUN) for clinical data was used in conjunc-
tion with the results of the first international workshop on
the International Criteria for the Diagnosis of Ocular
Sarcoidosis (IWOS) to score the location and activity of
the uveitis [4, 29].
Additionally, fluorescein angiography (FA, Topcon,
TRC-50 EX) or optical coherence tomography (OCT, Zeiss,
Stratus model 3000) was performed in 20 patients to detect
the presence of vasculitis, papillitis, or macular edema. In
16 cases, these findings were present bilateral. In total,
three patients refused FA; in the remaining three cases it
was thought that FA would have no beneficial effect.
The outcome of the specific inflammatory signs was
scored as resolved if complete clearance of the specific
inflammatory activity was seen; partial response if the
specific inflammatory activity had decreased; stabilization
if the specific inflammatory activity remained unchanged
and deterioration if the specific inflammatory activity had
increased.
Overall outcome of intraocular inflammatory signs was
scored as improvement if at least one of the scored
inflammatory signs showed a complete clearance in the
absence of deterioration of other inflammatory signs; partial
improvement if at least one of the scored inflammatory
signs improved in the absence of deterioration of other
inflammatory signs; stabilization if all inflammatory signs
remained unchanged; deterioration if at least one of the
inflammatory signs increased.
Pulmonary evaluation
Chest X-rays (CXR) were graded by one single person,
blinded to the clinical data and according to the standard
radiographic staging for sarcoidosis. According to the
Scadding radiographic staging system, five stages of radio-
graphical abnormality (0-IV) were recognized [27]. The
CXR stages of the included patients at the start of treatment
with adalimumab were, respectively: 16 patients (62%)
stage 0, four patients stage I (15%), four patients stage II
(15%), and two patients (8%) stage III.
Lung function measurements, including forced vital
capacity (FVC) were measured with a pneumotachograph
(Masterlab, Jaeger, Würzburg, Germany). The diffusing
capacity for carbon monoxide (DLCO) was measured by
the single-breath method (Masterlab, Jaeger, Würzburg,
Germany). Values were expressed as a percentage of
predicted values. Lung function characteristics of the
included patients are shown in Table 1.
Laboratory assays
The C-reactive protein (CRP) concentration and serum
levels of angiotensin converting enzyme (ACE) and soluble
interleukin-2 receptor (sIL-2R) were measured as described
in a previous study of our group [30].
Fatigue questionnaire
The Fatigue Assessment Scale (FAS) is a ten-item question-
naire to asses fatigue. Five questions reflecting physical
fatigue and five questions assessing mental fatigue [31].
The response scale is a five-point scale (1 never to 5
always); scores on the FAS can range from 10 to 50. The cut-
off score of the FAS was 22. A score below 22 indicates no
fatigue, whereas a score of 22 or higher indicates fatigue.
Statistical procedure
Differences between results at baseline, 6 months and
12 months were tested for statistical significance using the
Table 1 Summary of relevant clinical characteristics of the studied sarcoidosis patients and the effect on clinical manifestations after 6 and 12
months of treatment with adalimumab
Total population;
n=26; baseline
After 6 months treatment
with adalimumab
After 1 year treatment
with adalimumab (n=25)
DLCO (% predicted±SD) (normal >80% of predicted) 88±18 92±12 90±15
FVC (% predicted±SD) (normal >80% of predicted) 97±15 94±22 102±20
CRP (mean±SD) (2–9 μg·ml-1) 4.8±5.3 2.4±2.6* 3.6±4.4*
ACE (mean±SD) (9–25 U·L-1) 19±8 14±9* 15±10
sIL-2R (mean±SD) (240–3154 pg·ml-1) 2803±2224 1888±1537* 2188±1801*
FAS (mean±SD) (<22: no fatigue) 31.1±11.1 28.5±7.8* 28.9±10.0*
n: number; SD standard deviation; DLCO diffusion capacity for carbon monoxide; FVC forced vital capacity; CRP C-reactive protein; ACE serum
angiotensin-converting enzyme; sIL-2R soluble interleukin-2 Receptor; FAS Fatigue Assessment Scale
*p<0.01 compared with baseline
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paired t test in case of continuous variables or Chi-square
test in case of categorical variables. Statistical analyses
were performed using SPSS, version 15.0 for Windows
(SPSS Inc., Chicago, IL, USA). A p-value less than 0.05
was considered statistical significant.
Results
Relevant baseline clinical characteristics of the patients are
shown in Table 1. The details on uveitis manifestations at
baseline are included in Table 2. Mean age was 51±
15 years, nine patients were male. Before adalimumab was
initiated all patients were treated with oral corticosteroids
(starting dose 20–60 mg daily), if this did not have a
positive effect, MTX was added (12.5–15 mg once a week
orally). In eight cases, no MTX was added due to
earlier reported side-effects. One patient (number 16 in
Table 2) was previously treated with infliximab, however,
she developed antibodies after 2 years of treatment. To
reduce side-effects of treatment, adjunctive therapy in the
studied population (n=26) was tapered during treatment
with adalimumab: prednisone from 15.6±10.7 to 3.6±5.0
(p<0.01) and MTX from 9.6±5.5 to 5.6±4.1 (p<0.05),
respectively. The dosages of these drugs could be tapered
gradually within the first 6 months of treatment with
adalimumab. Thereafter, all patients remained on the same
(lower) dosage. After tapering, adjunctive therapy consisted
of only oral corticosteroids in four patients (5–10 mg daily);
corticosteroids together with methotrexate (MTX) in six
(mean dose MTX 8.6±4.4; range 5–15 mg daily), and
MTX alone in 12 patients (mean dose 7.6±2.4; range 5–
12.5 mg once a week orally). Four patients did not use
adjunctive therapy.
Table 2 provides the details on the intraocular inflam-
matory signs after 6 months of treatment with adalimumab.
The results after 12 months of treatment with adalimumab
are not shown in Table 2 for viewing purposes, since in

























1 F 44 0/1 1/0 1/0
2 F 34 0/1 1/1-
3 M 56 1/1 1/0 1/0
4 F 73 1/1 1/0 1/0
5 F 64 1/1 1/0 1/0 1/0 1/0
6 F 40 1/1 1/0 1/0
7 F 58 1/1 1/0 1/1-
8 F 79 1/1 1/0 1/0 1/0 1/0
9 F 47 1/1 1/1- 1/1- 1/0 1/0
10 F 35 1/0 1/0 1/0
11 F 41 1/1 1/0 1/0 1/0 1/0
12 M 69 1/1 1/1- 1/1-
13 F 59 1/1 1/0 1/0
14 M 67 1/1 1/0 1/0
15 M 33 1/1 1/1- 1/1- 1/1- 1/1-
16 F 56 0/1 1/0
17 F 79 0/1 1/1- 1/1-
18 M 46 1/1 1/0 1/0 1/0 1/0
19 F 39 0/1 1/0
20 M 43 1/1 1/0 1/0
21 F 37 1/0 1/0
22 F 23 1/1 1/0 1/0 1/0 1/0
23 F 49 0/1 1/0
24 M 64 1/1 1/0 1/0 1/1- 1/1-
25 M 63 1/0 1/0
26 M 41 1/0 1/0
F female; M male; OD right eye; OS left eye; m months; NLP no light perception; PAP papillitis; MAC macular edema; CHO choroidal
involvement; VAS vasculitis; VIT corpus vitreous cells; 1 present or yes; 0 absent or no; - partial improvement
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none of the patients the results regarding intraocular
inflammatory signs changed between 6 and 12 months.
Papillitis (the presence of inflammatory disc swelling) was
present in eight patients and resolved in seven patients (no
staining on FA), one had partial response (less staining on
FA). Eight patients had macular involvement, this resolved
in five of them (no leakage on FA or OCT) and a partial
response was seen in three patients (less leakage). An
example of resolved macular edema after treatment is
shown in Fig. 1. Choroidal involvement was present in 15
patients and resolved in ten (clearance of inflammatory
activity on funduscopy) whereas five had a partial response.
Vasculitis resolved in the one patient (no leakage on FA as
shown in Fig. 2). All of the five patients with vitreous
involvement showed a clearing of the vitreous of at least
two steps on fundus examination. The final outcome
regarding intraocular inflammatory signs showed improve-
ment in 22 patients (85%) and stabilization in four patients
(15%).
Patient number 22 developed bilateral glaucoma prior to
the start of adalimumab treatment, partly due to prednisone
therapy, and was successfully treated with a glaucoma
surgery procedure OD (Baerveldt implant) after eight
months of adalimumab treatment. This procedure was
performed successfully during adalimumab therapy and no
activation was seen postoperatively.
Table 1 displays the effect on clinical manifestations
after six and twelve months of treatment with adalimumab.
Inflammatory parameters demonstrated a positive reaction
during the anti-TNF-α treatment with adalimumab; the sIL-
2R increased in three of 26 patients and decreased or stayed
within normal limits in 23, whereas the ACE increased in
two patients and decreased or stayed within normal limits in
24 of the 26. CRP levels at baseline were elevated in seven
patients. Only one patient had as slightly elevated CRP
Fig. 1 Optical coherence
tomography (top) and fluorescein
angiography (bottom) of OS
showing macula edema before
(left) and after (right)
starting with adalimumab
Fig. 2 Patient 11: Fluorescein angiography showing vasculitis before
(top) and after (bottom) starting with adalimumab
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level after 6 months (14 mg/ml), whereas after 12 months in
all patients the CRP level was within the normal range.
Mean levels of CRP, ACE, and sIL-2R decreased signifi-
cantly during treatment with adalimumab.
None of the patients had an abnormal FVC (<80% of the
predicted value); eight patients appeared to have a
decreased diffusing capacity (DLCO<80% of the predicted
value) at baseline. After 6 months of treatment, seven of
eight patients demonstrated an improvement of at least
10%, whereas one patient remained stable. This increase in
DLCO in patients with a decreased TLCO was significant
(p<0.01) and still present after 1 year of treatment.
Most of the patients (n=21; 81%) suffered from fatigue
(FAS score ≥22), whereas 11 (42%) suffered from very
severe fatigue (FAS score >35). Fourteen of these 21
patients (67%) became less fatigued, four (19%) remained
stable, and three (14%) reported a minor increase of their
fatigue problems, as depicted by the FAS. The FAS score
decreased significantly during treatment with adalimumab
(p<0.01; Table 1).
Only one patient showed any signs of serious adverse
effects during adalimumab treatment. This patient (number
16) developed a severe side effect at the injection site which
led to the formation of a solid subcutaneous mass.
However, because of the favorable effect on the uveitis
she wanted to continue the treatment. Over time, this effect
on the skin decreased but was still present after 12 months
of treatment. Minor adverse effects, such as local skin
reactions occurred in four patients. These minor adverse
effects tapered off during the treatment period. All but one
patient continued treatment with adalimumab during the
follow-up period of 1 year. This one patient decided by
herself to discontinue the adalimumab after a period of
seven months into the treatment, although no side-effects
had occurred.
Discussion
In this prospective case series of sarcoidosis patients with
refractory chronic non-infectious posterior uveitis, adali-
mumab treatment appeared successful. For it not only
showed an improvement of the intraocular inflammatory
signs in the majority of patients (85%), but also appeared to
have a significantly positive effect on other sarcoidosis
related features, including inflammatory parameters, diffus-
ing capacity, and fatigue. Until the endpoint of the
evaluation (December 2010), no deteriorations were
reported in those successfully treated. Serious adverse
effects only occurred in one patient.
The presence of posterior uveitis is a predictor of a poor
visual prognosis, making treatment with immunosuppres-
sive drugs mandatory [6, 8]. All patients in our case series
had uncontrolled inflammation due to prednisone and
methotrexate resistance or intolerance, or a flare-up during
treatment, and therefore ocular inflammation after
12 months of follow-up would have been expected to be
worse without attempting a different therapy like with
adalimumab. Intraocular inflammatory signs at baseline
were modest in some of the included patients. However, in
the past they had posterior uveitis which again showed a
flare-up, also with respect to the serological inflammatory
signs, despite treatment. Delay in effective treatment could
lead to refractory inflammation, potentially leading to
further damage in the eye. Given the fact that further
therapeutic options were limited in these cases, early
adjunctive treatment was indicated. Furthermore, six of
the included patients responded to previous therapy with
immunosuppressive drugs, but demonstrated severe adverse
effects. Therefore, also in these patients, the intraocular
inflammatory signs were not pronounced.
If visually disabling cataract formation or glaucoma
develops in patients with uveitis, it is essential that no
ocular inflammatory activity is present at the time of
surgery [32]. One of our patients was successfully treated
with a glaucoma surgery procedure (Baerveldt implant)
during adalimumab therapy and no activation was seen
postoperatively.
Disabling side-effects of steroid treatment, including
cataract formation, glaucoma, osteoporosis, Cushing’s
syndrome or diabetes mellitus, and the refractory character
of the uveitis in some sarcoidosis patients, stress the need
for alternatives. In the patients of this case series,
adalimumab appeared to be a well-tolerated alternative
and the dosage of both prednisone and MTX could be
tapered down significantly during this treatment.
Previously, adalimumab also appeared to be an appro-
priate alternative for infliximab in patients with Crohn’s
disease who first responded quite well, but had to stop due
to antibody formation and/or the development of an allergic
reaction and became intolerant to infliximab [33]. The
decision to switch to another TNF-α inhibitor has not been
studied systematically in sarcoidosis. However, switching
from infliximab to adalimumab has been successful for
some patients in case of allergic reactions [34]. In our
institute, we successfully switched therapy in five patients
(including patient 16 of the present study) whom had
formed antibodies against infliximab (data not shown).
Previously, the combination of anti-TNF-α therapy and a
cytotoxic drug has been shown to be superior to anti-TNF-α
therapy alone [35]. However, this was not reported in all
situations [36, 37]. In our patients, the immunosuppressive
medication as taken at the start of anti-TNF-α therapy was
continued unless side effects occurred or contra-indications
existed. In those cases the dosage of the MTX and
prednisone was tapered off as described in the results section.
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It remains unclear how long anti-TNF-α therapy in a
responding patient should be continued. In sarcoidosis,
longer follow-up data are needed to determine the optimal
treatment period to avoid disease relapse or deterioration. In
our experience, treatment should be continued for at least a
year instead of a shorter period as in rheumatoid arthritis.
A recent randomized controlled trial with infliximab versus
placebo in chronic pulmonary sarcoidosis patients showed a
change in FVC, the primary end point of that study [12].
Although in our studied population none of the patients had
a decreased FVC (<80% of predicted), eight showed a
decreased diffusing capacity (<80% of predicted) at baseline.
These latter patients demonstrated a significant improvement
of the DLCO after 6 months and 1 year of treatment with
adalimumab. Unfortunately, the DLCO was not evaluated in
the previously mentioned infliximab study [12].
Several reports suggest that CRP can predict response to
anti-TNF-α therapy in different inflammatory diseases [38–
42]. In line with this, in the present study, a decrease of the
CRP was demonstrated after 6 months as well as after
1 year of treatment with adalimumab. Also, the decrease in
ACE and sIL2-R and the improvement of fatigue during
treatment with adalimumab is in accordance with findings
of previous studies with anti-TNF-α agents, mainly
infliximab, in sarcoidosis patients [11, 43]. Thus, although
the primary reason for initiating treatment with adalimumab
was refractory uveitis, the treatment also resulted in the
improvement of systemic (inflammatory) manifestations of
sarcoidosis.
This study has several limitations. Since during the
follow-up period every sarcoidosis patient with refractory
chronic non-infectious uveitis (as defined previously) in our
clinic was treated with adalimumab in the absence of
contra-indications, no control group could be evaluated.
Also, the clinical examiner was not masked in grading
response to treatment.
In conclusion, in this case series of sarcoidosis patients
with refractory chronic non-infectious posterior uveitis,
adalimumab appeared to be successful by showing im-
provement of intraocular inflammatory signs. Moreover,
other relevant clinical indicators of disease activity im-
proved as well. Future randomized studies are needed to
determine optimal dosage, dose interval, and duration of
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